PDCD1 and B-cell chronic lymphocytic leukemia: Notably, in chronic lymphocytic leukemia- (CLL-) derived monocytes, triggering the PD-1 checkpoint by using the bioactive recombinant PD-L1 protein hampers glycolysis (reduces glucose uptake, glucose transporters, and expression of glycolytic molecules) and shifts their metabolism toward OXPHOs, which may suggest the PD-1/PD-L1 axis as a novel immune metabolic player in myeloid cells [81, 82].